Harvard Bioscience, Inc. (NASDAQ:HBIO) Director Bertrand Loy purchased 6,616 shares of Harvard Bioscience stock in a transaction on Friday, November 8th. The stock was bought at an average price of $2.64 per share, for a total transaction of $17,466.24. The purchase was disclosed in a document filed with the SEC, which is available through this link.
Bertrand Loy also recently made the following trade(s):
- On Wednesday, November 13th, Bertrand Loy purchased 6,100 shares of Harvard Bioscience stock. The stock was bought at an average price of $2.52 per share, for a total transaction of $15,372.00.
- On Monday, November 11th, Bertrand Loy purchased 12,855 shares of Harvard Bioscience stock. The stock was bought at an average price of $2.59 per share, for a total transaction of $33,294.45.
- On Friday, September 13th, Bertrand Loy purchased 7,372 shares of Harvard Bioscience stock. The stock was bought at an average price of $3.11 per share, for a total transaction of $22,926.92.
- On Wednesday, September 11th, Bertrand Loy purchased 15,590 shares of Harvard Bioscience stock. The stock was bought at an average price of $3.01 per share, for a total transaction of $46,925.90.
Shares of Harvard Bioscience stock traded up $0.23 on Friday, hitting $2.98. 3,062 shares of the company’s stock traded hands, compared to its average volume of 97,838. Harvard Bioscience, Inc. has a one year low of $1.51 and a one year high of $4.66. The company has a debt-to-equity ratio of 0.78, a current ratio of 2.41 and a quick ratio of 1.30. The company has a fifty day moving average of $2.85 and a two-hundred day moving average of $2.54. The company has a market capitalization of $95.55 million, a price-to-earnings ratio of 19.87 and a beta of 1.49.
A number of equities research analysts have commented on the company. ValuEngine lowered Harvard Bioscience from a “buy” rating to a “hold” rating in a research report on Tuesday, October 22nd. Benchmark reiterated a “buy” rating on shares of Harvard Bioscience in a research report on Friday, July 19th. Finally, Zacks Investment Research upgraded Harvard Bioscience from a “hold” rating to a “buy” rating and set a $3.00 target price on the stock in a research report on Tuesday.
About Harvard Bioscience
Harvard Bioscience, Inc provides scientific instruments, systems, software, and services used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, sample preparation plates and columns, and electroporation and electrofusion instruments under the Biochrom, BioDrop, Hoefer, Scie-plas, QuikPrep, and BTX brands.
Featured Article: Outstanding Shares, Buying and Selling Stocks
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.